P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION

• U. Jaeger,
• C. Broome,
• R. Go,
• A. Patriarca,
• A. Roeth,
• Q. Chang,
• N. Weedin,
• P. Adams,
• E. Cahir-McFarland,
• H.-A. Kroon

Affiliations

U. Jaeger

1 Medical University of Vienna, Vienna, Austria

C. Broome

2 MedStar Georgetown University Medical Center, Washington, DC

R. Go

3 Mayo Clinic, Rochester, MN, United States of America

A. Patriarca

4 AOU Maggiore della Carita, Novara, Italy

A. Roeth

5 Klinik für Hämatologie und Stammzelltransplantation, Essen, Germany

Q. Chang

6 Annexon Biosciences, South San Francisco, CA, United States of America

N. Weedin

6 Annexon Biosciences, South San Francisco, CA, United States of America

P. Adams

6 Annexon Biosciences, South San Francisco, CA, United States of America

E. Cahir-McFarland

6 Annexon Biosciences, South San Francisco, CA, United States of America

H.-A. Kroon

6 Annexon Biosciences, South San Francisco, CA, United States of America